Organization | Fundación GECP

Fundación GECP Report issue

Foundation Phase 2 Phase 3

Founded: Barcelona Spain (1991)

Organization Overview

First Clinical Trial

2019

NCT03836066

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Fundación GECP | Fundación GECP Investigator | Fundación GECP President

Active Ingredients

Drugs in Phase 3 Trials (3)

carboplatin (paraplatin) (7 trials)

nivolumab (opdivo) (4 trials)

paclitaxel (taxol) (5 trials)

Drugs in Phase 2 Trials (11)

atezolizumab (Tecentriq) (3 trials)

bevacizumab (avastin) (2 trials)

bintrafusp alfa (1 trial)

brigatinib (alunbrig) (1 trial)

cisplatin (platinol) (1 trial)

etoposide (vepesid) (1 trial)

ipilimumab (yervoy) (1 trial)

lenvatinib (lenvima) (1 trial)

pembrolizumab (keytruda) (1 trial)

pemetrexed (alimta) (2 trials)

sotorasib (LUMAKRAS) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial APIs: 14